Skip to main content
Acta Bio Medica : Atenei Parmensis logoLink to Acta Bio Medica : Atenei Parmensis
. 2020 Nov 9;91(Suppl 13):e2020004. doi: 10.23750/abm.v91i13-S.10602

Genetic analysis of genes associated with Mendelian dementia

Astrit Dautaj 1, Luana Mandarà 2, Vittorio Tassi 3, Kristjana Dhuli 1, Matteo Bertelli 1,4,5
PMCID: PMC8023123  PMID: 33170157

Abstract

Background and aim:

Dementia is a disease associated with cognitive and/or behavioral changes that interfere with the ability to perform daily activities. Alzheimer’s disease is the most common type of dementia. The aim of this mini-review is to summarize all the syndromes characterized by dementia and for which the associated gene is known.

Methods:

We searched those syndromes in PubMed and OMIM database.

Results:

Two forms of dementia exist: the multifactorial dementia results from the interaction of different genetic and environmental factors, the hereditary dementia associated with a single gene. Individuals with a family history of dementia and early onset of the disease are more likely to have a hereditary form of dementia. Dementias are mainly autosomal dominant, but they can also be autosomal recessive or X-linked.

Conclusions:

Since dementia has high clinical and genetic heterogeneity, the use in diagnostics of a large panel of genes may greatly help to speed up the determination of the molecular diagnosis and/or establish a risk of recurrence in family members for the purpose of planning appropriate preventive and/or therapeutic measures. (www.actabiomedica.it)

Keywords: Mendelian dementia, Alzheimer disease, Parkinson disease


Dementia is a disease associated with cognitive and/or behavioral changes that interfere with the ability to perform daily activities (1). Dementia occurs in 5-7% of individuals over 60 years of age (2). Alzheimer’s disease (AD) is the most common type of dementia (about 60-80% of cases), of which <10% have early onset. It is familial in 25% cases (3) and is a degenerative dementia characterized by cortical disorders such as agnosia, aphasia and apraxia. Other degenerative dementias are frontotemporal dementia (Pick’s disease, primary progressive aphasia, semantic dementia), progressive supranuclear paralysis, Lewy’s body dementia, Parkinson’s dementia, Huntington’s disease, prion disease and cortical-basal degeneration. There are also reversible dementias and vascular dementias (4,5). Pharmacological treatment is supportive. Diagnosis of dementias involves neurological examination, including mental status examination, neuropsychological evaluation, laboratory tests and neuroimaging. The differential diagnosis of Alzheimer’s disease includes other causes of dementia, particularly treatable forms of cognitive decline that include depression, chronic drug intoxication, chronic central nervous system infection, thyroid disease, vitamin deficiencies, inflammatory central nervous system angioitis and normal pressure hydrocephalus. A distinction must also be made between different forms of dementia (3). Multifactorial forms of dementia, resulting from the interaction of different genetic and environmental factors, and hereditary forms of dementia are known (6). Individuals with a family history of dementia and early onset of the disease are more likely to have a hereditary form of dementia (1). Dementias are mainly autosomal dominant, but they can also be inherited in an autosomal recessive or X-linked manner (Table 1). Reference guidelines for genetic testing are contained in “Genetics Home Reference” (ghr.nlm.nih.gov) and Gene Reviews (3). Detection of variations in the genes in Table 1 is based on analysis of a multi-gene panel by next generation sequencing of the coding regions and their intron-exon junctions. Testing aims to identify variants in genes known to be associated with dementia in subjects suspected to have Mendelian dementia.

Table 1.

Syndromes characterized by dementia for which the genetic basis is known

Gene OMIM# Gene Inheritance Phenotype OMIM# Phenotype/Reference Gene function (https://www.genecards.org/)
APOE 107741 ADo AD2 104310 Essential for catabolism of triglyceride-rich lipoproteins
APP 104760 ADo AD 104300 Neurite growth, neuronal adhesion, axonogenesis, synaptogenesis
C9orf72 614260 ADo FTDALS1 105550 Regulation of endosomal trafficking, autophagy
CHMP2B 609512 ADo FTD3 600795 Involved in recycling/degradation of growth factor receptors, lysosomal enzymes, lipids
CSF1R 164770 ADo HDLS 221820 Cytokine controlling macrophages production, differentiation, function
DCTN1 601143 ADo Perry syndrome 168605 Endoplasmic reticulum-to-Golgi transport, movement of lysosomes/endosomes, spindle formation, chromosome movement, nuclear positioning, axonogenesis
FUS 137070 ADo, AR ALS6 608030 Crucial for dendritic spine formation/stability, RNA transport/stability, synaptic homeostasis
GRN 138945 ADo Frontotemporal lobar degeneration with TDP43 inclusions 607485 Inflammation modulation in neurons by preserving neuron survival, axonal outgrowth, neuronal integrity
MAPT 157140 ADo FTD, Pick disease of brain 600274, 172700 Neuronal polarity establishment/maintenance
PRNP 176640 ADo HDL1, spongiform encephalopathy with neuropsychiatric features 603218, 606688 Neuronal development, synaptic plasticity. Required for neuronal myelin sheath maintenance
PSEN1 104311 ADo AD, FTD 607822, 600274 Regulation of neurite outgrowth, presynaptic facilitation, spike transmission, synaptic vesicles replenishment
PSEN2 600759 ADo Alzheimer disease-4 606889 Modulation of Ca2+ ion shuttling between endoplasmic reticulum and mitochondria
SIGMAR1 601978 ADo Frontotemporal lobar degeneration-motor neuron disease (7) Necessary for axonal retrograde movement of mitochondria in motor neurons
SORL1 602005 ADo Late-onset AD / Positive regulation of BDNF signaling
SQSTM1 601530 ADo FTDALS3 616437 Formation/degradation of ubiquitin-containing inclusions, involved in cell differentiation, apoptosis, immune response, regulation of K+ channels
TARDBP 605078 ADo ALS10 612069 Splicing regulation of mRNAs encoding proteins involved in neuronal survival
TREM2 605086 AD PLOSL2 618193 Regulation of microglial proliferation, chemotaxis, outgrowth, activation and phagocytosis of apoptotic neurons and myelin debris, neuronal synapses during brain development
TYROBP 604142 AR PLOSL1 221770 Promotion of neuronal apoptosis during brain development and proinflammatory responses in microglia after nerve injury
UBQLN2 300264 XLD ALS15 300857 Regulation of ubiquitin-proteasome system, autophagy, endoplasmic reticulum-associated protein degradation pathways
VCP 601023 ADo IBMPFD1 167320 Ubiquitin-dependent sorting of membrane proteins to lysosomes

AD = Alzheimer’s dis ease; Ado = autosomal dominant; FTDALS = frontotemporal dementia and/or amyotrophic lateral sclerosis; FTD = frontotemporal dementia; HDLS = hereditary diffuse leukoencephalopathy with spheroids; ALS = amyotrophic lateral sclerosis with/without frontotemporal dementia; HDL = Huntington disease-like; PLOSL = polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy; IBMPFD = inclusion body myopathy with early-onset Paget disease with/without frontotemporal dementia.

Our NGS test has an analytical sensitivity and specificity ≥99%. On the other hand, diagnostic sensitivity in individuals with early-onset familial Alzheimer’s disease with a pathogenic variant in APP, PSEN1 or PSEN2 can be identified in 40-80% of cases (8). A pathogenic variant can be identified in about 65% of cases of frontotemporal dementia (9). A genetic cause can be identified in about 10-15% of cases of prion disease (10). The diagnostic specificity of Alzheimer’s disease is about 70% (11).

Although dementia has high clinical and genetic heterogeneity, our test makes it possible to determine the molecular diagnosis of new subjects and/or establish a risk of recurrence in family members for the purpose of planning appropriate preventive and/or therapeutic measures.

Conflict of interest:

Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article

References

  • 1.Loy CT, Schofield PR, Turner AM, Kwok JB. Genetics of dementia. Lancet. 2014;383:828–40. doi: 10.1016/S0140-6736(13)60630-3. [DOI] [PubMed] [Google Scholar]
  • 2.Wszolek Z, Konno T. Perry syndrome. GeneReviews. 2010 Available at: https://www.ncbi.nlm.nih.gov/books/NBK47027/ [Google Scholar]
  • 3.Bird TD. Alzheimer disease overview. GeneReviews. 1998 Available at: https://www.ncbi.nlm.nih.gov/books/NBK1161/ [Google Scholar]
  • 4.Kitagaki H, Mori E, Ishii K, Yamaji S, Hirono N, Imamura T. CSF spaces in idiopathic normal pressure hydrocephalus: morphology and volumetry. AJNR Am J Neuroradiol. 1998;19:1277–84. [PMC free article] [PubMed] [Google Scholar]
  • 5.Barker W, Luis CA, Kashuba A, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the state of Florida brain bank Alzheimer. Dis Assoc Disord. 2002;16:203–12. doi: 10.1097/00002093-200210000-00001. [DOI] [PubMed] [Google Scholar]
  • 6.Fenoglio C, Scarpini E, Serpente M, Galimberti D. Role of genetics and epigenetics in the pathogenesis of Alzheimer’s disease and frontotemporal dementia. J Alzheimers Dis. 2018;62:913–32. doi: 10.3233/JAD-170702. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Luty AA, Kwok JB, Dobson-Stone C, et al. Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease. Ann Neurol. 2010;68:639–49. doi: 10.1002/ana.22274. [DOI] [PubMed] [Google Scholar]
  • 8.Janssen JC, Beck JA, Campbell TA, et al. Early onset familial Alzheimer’s disease: mutation frequency in 31 families. Neurology. 2003;60:235–9. doi: 10.1212/01.wnl.0000042088.22694.e3. [DOI] [PubMed] [Google Scholar]
  • 9.Olszewska DA, Lonergan R, Fallon EM, Lynch T. Genetics of frontotemporal dementia. Curr Neurol Neurosci Rep. 2016;16:107. doi: 10.1007/s11910-016-0707-9. [DOI] [PubMed] [Google Scholar]
  • 10.Mackenzie G, Will R. Creutzfeldt-Jakob disease: recent developments. F1000Res. 2017;6:2053. doi: 10.12688/f1000research.12681.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Nicolas G, Wallon D, Charbonnier C, et al. Screening of dementia genes by whole-exome sequencing in early-onset Alzheimer disease: input and lessons. Eur J Hum Genet. 2016;24:710–6. doi: 10.1038/ejhg.2015.173. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Acta Bio Medica : Atenei Parmensis are provided here courtesy of Mattioli 1885

RESOURCES